Were James Kasinger’s CRISPR Therapeutics (CRSP) share sales discretionary trades?

No, the filing states the sales were not discretionary trades by James Kasinger. The 2,112 Common Shares sold were required under the company’s RSU Settlement Policy to cover tax withholding obligations arising from the vesting of restricted stock units granted to him.

CRISPR Therapeutics (CRSP) legal chief reports RSU share vesting and tax sale

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported a mix of equity transactions involving company stock. On February 18, 2026, he acquired 3,825 Common Shares through the exercise and settlement of restricted stock units at a price of $0.00 per share, increasing his direct holdings to 87,227 Common Shares. On February 19, 2026, 2,112 Common Shares were sold at an average price of $52.58 per share to cover tax withholding obligations related to the RSU vesting, as required by the company’s RSU Settlement Policy and not as a discretionary trade. After these transactions, he directly owned 85,115 Common Shares.

Insider Trade Summary

Net Seller: 2,112 shares ($111,049)

Net Sell 3 txns

Insider KASINGER JAMES R.

Role General Counsel and Secretary

Sold 2,112 shs ($111K)

Type	Security	Shares	Price	Value
Sale	Common Shares	2,112	$52.58	$111K
Exercise	Restricted Stock Units	3,825	$0.00	--
Exercise	Common Shares	3,825	$0.00	--

Holdings After Transaction: Common Shares — 85,115 shares (Direct); Restricted Stock Units — 0 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.

Form 4 Insider Transactions: What Each Field Means →

02/20/2026 - 05:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KASINGER JAMES R.

(Last)

(First)

(Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON

02127

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	General Counsel and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	02/18/2026		M		3,825	A	⁽¹⁾	87,227	D
Common Shares	02/19/2026		S		2,112⁽²⁾	D	$52.58	85,115	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	02/18/2026		M			3,825	⁽³⁾	⁽³⁾	Common Shares	3,825	⁽¹⁾	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

2. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

3. This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.

	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did CRISPR Therapeutics (CRSP) executive James Kasinger report in this Form 4?

James R. Kasinger reported both an RSU-related share acquisition and a tax-related share sale. He acquired 3,825 Common Shares from restricted stock units and sold 2,112 Common Shares to satisfy tax withholding obligations mandated by the company’s RSU Settlement Policy.

How many CRISPR Therapeutics (CRSP) shares did James Kasinger sell and at what price?

James Kasinger reported selling 2,112 Common Shares of CRISPR Therapeutics at an average price of $52.58 per share. According to the filing, this sale was executed solely to cover tax withholding obligations tied to restricted stock unit vesting under the company’s RSU Settlement Policy.

How many CRISPR Therapeutics (CRSP) shares does James Kasinger own after these transactions?

After the reported transactions, James Kasinger directly owns 85,115 Common Shares of CRISPR Therapeutics. His holdings increased from RSU settlement to 87,227 shares, then decreased when 2,112 shares were sold to satisfy tax withholding obligations on the vested restricted stock units.

What restricted stock unit (RSU) award is referenced in James Kasinger’s CRSP Form 4?

The Form 4 references an RSU award granted on February 18, 2022 for 15,300 Common Shares. The award vests in four equal installments on February 18 of 2023, 2024, 2025, and 2026, creating multiple vesting events that can trigger associated tax withholding share sales.

How many restricted stock units did James Kasinger convert into CRISPR Therapeutics (CRSP) shares?

James Kasinger converted 3,825 restricted stock units into 3,825 Common Shares. The transaction is reported at a price of $0.00 per share, reflecting that RSU settlement is not a cash purchase but a conversion from a derivative right into actual Common Shares.